CareLit · DOI-Nachweis · Pneumologie
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced Non-Small Cell Lung Cancer (NSCLC) patient
DOI 10.1055/s-0036-1572244
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ von Pawel, S Kraff, JR Fischer, W Eberhardt, T Gauler, L Müller, N Reinmuth, M Reck, M Kimmich, F Mayer, HG Kopp, DM Behringer, YD Ko, M Frueh, RA Hilger, M Roessler, B Moritz, U Jaehde, M Joerger
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Variability of chemotherapy exposure may cause severe toxicity or lack of efficacy. Paclitaxel (PTX) exposure (time above a plasma concentration of 0.05mM, Tc > 0.05) has been shown to predict toxicity. Whereas carboplatin dose is adapted to kidney function, PTX dosing only accounts for body-surface area. We developed a PTX dosing algorithm for avoidance of supra- or subtherapeutic PTX exposure based on…
Zitieren
Zitierempfehlung
J von Pawel, S Kraff, JR Fischer, W Eberhardt, T Gauler, L Müller, N Reinmuth, M Reck, M Kimmich, F Mayer, HG Kopp, DM Behringer, YD Ko, M Frueh, RA Hilger, M Roessler, B Moritz, U Jaehde, M Joerger (2016) Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced Non-Small Cell Lung Cancer (NSCLC) patient. Pneumologie (02). https://doi.org/10.1055/s-0036-1572244
Mit CareLit weiterarbeiten